Core Insights - The price of experimental monkeys, specifically the crab-eating macaque, has surged above 100,000 yuan, marking a significant increase of over 30% from previous prices, leading to a budget shortfall for companies [1][2] - The supply of experimental monkeys is critically low, with a reported annual demand-supply gap of approximately 10,000 monkeys in China, exacerbated by the increasing reliance on these animals for drug safety evaluations [10][11] - The cyclical nature of monkey prices is influenced by a seven-year breeding cycle, making it difficult for breeding companies to respond to market demands in a timely manner [6][7] Price Trends - The price of crab-eating macaques has fluctuated dramatically over the past decade, with a 14-fold increase since 2017, and current prices are expected to stabilize between 70,000 to 150,000 yuan in the next two to three years [2][5] - The peak price reached 200,000 yuan in 2022 and 2023, but has since decreased to around 100,000 yuan, still significantly impacting the cost structure of drug development projects [3][6] Supply Chain Dynamics - The concentration of monkey breeding facilities has increased, with major CRO companies acquiring a significant portion of the available monkeys, leading to a tighter market for smaller companies seeking to procure these animals [9][10] - The breeding cycle for crab-eating macaques is lengthy, taking approximately 6 to 7 years from birth to maturity, which complicates the ability of breeding companies to scale up production in response to rising demand [6][7] Industry Implications - The high cost of experimental monkeys now constitutes a core part of the toxicology testing budget, with estimates suggesting that a single project may require four to five million yuan just for safety evaluation experiments [3][4] - The ongoing demand for innovative drug development, particularly in areas such as antibody drugs and gene therapy, continues to drive the need for crab-eating macaques in preclinical testing [7][11] Future Outlook - The industry is facing a potential decline in self-sustaining breeding capacity, with projections indicating that the annual production of self-bred crab-eating macaques may fall below 10,000 in the next two to three years if current trends continue [7][10] - Companies are urged to consider long-term strategies for breeding and procurement to mitigate the impact of fluctuating prices and supply shortages in the future [6][9]

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has received approval from the National Medical Products Administration for clinical trials of HLX37 injection for treating advanced/metastatic solid tumors [1][4]. Group 1: Product Development - HLX37 is a recombinant humanized bispecific antibody targeting PD-L1 and VEGF, aimed at treating advanced/metastatic solid tumors [3][6]. - Preclinical studies indicate that HLX37 can inhibit tumor growth and has good safety profiles [3][6]. - The company plans to initiate Phase I clinical trials for HLX37 in China once conditions are met [3][6]. Group 2: Financial Investment - As of October 2025, the cumulative R&D investment for HLX37 is approximately 50.23 million yuan [3][6]. - According to IQVIAMIDAS™ data, the global sales forecast for PD-1/PD-L1 and VEGF bispecific antibody products in 2024 is around 920,000 USD [3][6]. Group 3: Company Performance - During the Q3 earnings call on November 20, the company reported that innovative drug revenue exceeded 6.7 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 18.09% [3][6]. - The company has set a target for a 20% compound annual growth rate for innovative drug revenue from 2025 to 2027 [3][6]. - Future strategies include increasing R&D investment, accelerating clinical and commercialization processes for key projects, and strengthening global operations to drive steady growth in the innovative drug business [3][6].

Core Viewpoint - The article discusses the increasing interaction between Chinese innovative drugs and global patients, highlighting the appeal of CAR-T therapy in China for international cancer patients due to lower costs and efficient treatment processes [1][3][4]. Group 1: CAR-T Therapy in China - CAR-T therapy is a personalized treatment that enhances the ability of T-cells to recognize and kill tumors, with significant development concentrated in China and the US [3]. - The cost of CAR-T drugs in China ranges from 1 million to 1.3 million yuan, approximately one-third of the price in the US, making it a more attractive option for patients [4][5]. - Over the past year, more than 100 overseas patients have consulted with medical institutions in China, with around 90% of completed CAR-T treatments being for international patients [6]. Group 2: Growth of China's Oncology Drug Ecosystem - China's oncology sector has attracted substantial R&D funding, with advancements spanning from early screening to late-stage treatment [7]. - The approval of new indications for existing drugs, such as the combination therapy for non-small cell lung cancer, showcases the rapid development in the oncology field [7]. - The increasing recognition of Chinese pharmaceutical innovation is evidenced by the number of breakthrough therapy designations granted by the FDA to Chinese products [11]. Group 3: International Expansion of Chinese Drugs - Chinese companies are increasingly recognized for their innovation, with significant international collaborations and licensing agreements, such as the partnership between Innovent Biologics and Takeda Pharmaceuticals [10]. - The global market for Chinese CAR-T products is expanding, with companies like Legend Biotech achieving substantial sales figures in the US [10]. - The trend of Chinese pharmaceutical companies seeking international markets is driven by the need for growth outside the competitive domestic landscape [13]. Group 4: Challenges and Opportunities - While the Chinese pharmaceutical industry is making strides, challenges remain in establishing a robust international presence and navigating regulatory environments [12]. - The potential for growth in medical tourism in China is significant, but improvements in visa policies and treatment timelines are necessary to enhance competitiveness [8]. - The future of China's innovative drug sector is uncertain, with investors closely monitoring government policies and market dynamics [13].

来源：上海证券报微信公众号 今日提示 •2025企业家博鳌论坛系列活动12月2日至12月5日在海南博鳌举办。 •2025年中国国际海事会展12月2日至12月5日在上海举办。 •据网络实时数据，截至12月1日18时30分，影片《疯狂动物城2》票房突破20亿元。 •沐曦股份发行初步询价日为12月2日，申购日为12月5日。 •12月1日，DeepSeek同时发布两个正式版模型：DeepSeek-V3.2和DeepSeek-V3.2-Speciale。 上证精选 •广期所发布通知，对多晶硅期货PS2601合约的交易保证金标准及交易限额作如下调整：自2025年12月3 日结算时起，多晶硅期货PS2601合约投机交易保证金标准调整为13%，套期保值交易保证金标准调整为 12%。自2025年12月3日交易时起，非期货公司会员或者客户在多晶硅期货PS2601合约上单日开仓量不 得超过500手。 •上海市政府近日印发《上海市引进人才申办本市常住户口办法》《持有〈上海市居住证〉人员申办本 市常住户口办法》，12月1日起施行。《办法》第三条明确规定，在本市行政区域内注册的用人单位引 进本市紧缺急需的国内优秀人才，可以申办本市常住户 ...

Group 1 - The report emphasizes that the adjustment in the Hong Kong stock market in November has created space for growth in 2026, with a focus on sectors such as AI, materials, and innovative pharmaceuticals [2][64][82] - The report highlights the importance of AI in driving productivity improvements across industries, particularly in the software sector, where per capita income has increased from 750,000 to 870,000 yuan over the past five years [1][59][61] - The report notes that the "anti-involution" trend is expected to positively impact PPI recovery and overall corporate profitability, with a significant reduction in losses for struggling companies [1][55][58] Group 2 - The report suggests that the AI sector remains a key focus for 2026, driven by the need for domestic hardware production and the expectation of more AI applications being implemented [2][82] - The materials and industrial sectors are expected to benefit from the anti-involution trend, with upstream metals and certain industrial enterprises poised to gain [2][82] - The report indicates that the innovative pharmaceutical sector is stable and worth holding, with potential for growth if new business development projects are released [2][82] Group 3 - The report discusses the performance of the Hong Kong stock market in November, noting a slight adjustment of 0.2% in the Hang Seng Index, with significant sector differentiation [64][66] - It highlights that the consumer and innovative pharmaceutical sectors showed positive performance, while technology and automotive sectors faced declines [64][66] - The report mentions that the inflow of southbound funds reached 117.2 billion yuan in November, indicating strong willingness from Chinese capital to invest in Hong Kong stocks despite market downturns [75][82]

Core Viewpoint - The A-share market has shown a structural differentiation in the first 11 months of this year, with new economy sectors like artificial intelligence and innovative pharmaceuticals leading the market, while traditional sectors like liquor have underperformed, creating a stark contrast [2][3]. Investment Strategy - The significant differentiation between new and old market drivers has become a key factor in investment success this year. The rapid expansion of ETF management scale and the issuance of floating fee rate funds have led public funds to focus more on performance benchmarks, resulting in clearer investment styles and directions [3][4]. Core and Satellite Strategy - The "core + satellite" strategy is recommended for investors as a stable allocation method. Core assets should be balanced and historically stable with low drawdowns, while satellite assets should target emerging industries with greater return elasticity. This approach is essential for funds to generate excess returns across different market conditions [4]. Performance of Fund - The Guangfa Multi-Factor Fund (002943) has shown impressive long-term performance, with a net value growth rate of 376.1% from early 2018 to November 28, 2025, translating to an annualized return of 21.82%. It has consistently outperformed major indices during bull and bear markets [5][8][9]. Fund Management - The fund is managed by experienced professionals, including Yang Dong, who has 19 years of experience in investment management. The fund's holdings are well-diversified across 30 industries, and it employs a dynamic adjustment strategy based on a "macro four-cycle" framework to capture excess returns [10][11]. Sector Allocation - The fund has effectively managed its exposure to the electronics sector, increasing its allocation significantly in 2024 and adjusting it based on market performance. This strategic allocation has allowed the fund to maintain a competitive edge [12]. Satellite Asset Tools - The Guangfa team has developed Smart Beta and thematic enhancement products to provide investors with tools for enhanced returns. These products aim to achieve stable excess returns through a combination of strategies, catering to various investor preferences [17][18]. New Product Launch - The Guangfa Quality Selection Fund, utilizing a "PB-ROE" strategy, has been launched to adapt to changing market preferences, focusing on quality and valuation. This strategy aims to identify undervalued companies with strong profitability potential [23][24].

Group 1 - The pharmaceutical commercial sector showed strong performance, with Haiwang Biological achieving a "five consecutive limit-up" status, closing with over 290,000 sealed orders on the limit-up board [2][4] - Haiwang Biological's market capitalization reached 10.814 billion, with a trading volume ratio of 0.78 and a price increase of 9.89% [3] - The demand for cold medicine is expected to exceed market expectations due to a significant rise in flu cases, with the flu positivity rate nearing 45% nationally [8] Group 2 - The Fujian Free Trade Zone sector performed well, with stocks like Jiarong Technology and Haiwan Food hitting limit-up, contributing to a 51% increase in the sector since the beginning of the year [9][10] - Recent policies in Fujian aim to enhance digital economy competitiveness and promote the development of computing infrastructure, targeting a public computing scale of over 12 EFLOPS by the end of 2027 [12] - The Fujian provincial government is focusing on developing multiple trillion-yuan industrial clusters, including biomedicine and artificial intelligence, to strengthen the local economy [13]

Core Viewpoint - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.24% while the Hang Seng Tech Index fell by 0.37% [1] Group 1: Market Performance - The Hang Seng Index increased by 0.24% [1] - The Hang Seng Tech Index decreased by 0.37% [1] Group 2: Sector Performance - The innovative drug sector experienced a decline, with Genscript Biotech falling over 6% [1] - Same-Origin Health fell by more than 5% [1] - NIO saw a decline of over 6% [1]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Core Viewpoint - Zai Jian Pharmaceutical's stock has experienced a year-to-date increase of 71.11%, but has seen a slight decline of 0.94% over the past five trading days, indicating volatility in its recent performance [1] Company Overview - Zai Jian Pharmaceutical, established on March 18, 2009, and listed on January 23, 2020, is located in Kunshan, Jiangsu Province. The company focuses on the research, production, and sales of chemical and biological new drugs, with 99.97% of its revenue derived from pharmaceuticals [1][2] - As of September 30, 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, which is an increase of 4.58% compared to the previous period [2] Stock Performance - As of December 2, Zai Jian Pharmaceutical's stock price was 106.62 yuan per share, with a market capitalization of 28.22 billion yuan. The trading volume was 1.02 billion yuan, with a turnover rate of 0.36% [1] - The stock has been featured on the "Dragon and Tiger List" once this year, with the most recent appearance on October 31, where it recorded a net purchase of 187 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 0.16% to 8,809, while the average circulating shares per person decreased by 0.16% to 30,049 shares [2] - The top ten circulating shareholders include various funds, with notable changes in holdings, such as a decrease in shares held by China Europe Medical Health Mixed A and an increase in shares held by Huatai-PineBridge Innovation Medicine Mixed A [2]